Kim M. Kerr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kim M. Kerr has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Michael M. Madani
Division of Cardiovascular and Thoracic Surgery, University of California San Diego, La Jolla, CA, USA
6 shared publications - Demosthenes G. Papamatheakis
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine University of California San Diego San Diego California USA
5 shared publications - Jenny Z. Yang
Department of Pulmonary & Critical Care Medicine, University of California San Diego Health, 9434 Medical Ctr Dr, San Diego, CA 92037, USA
5 shared publications - Nick H. Kim
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, CA, USA
5 shared publications - David S. Poch
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine University of California San Diego San Diego California USA
4 shared publications - William R. Auger
Emeritus Professor of Medicine, University of California San Diego USA
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Pulmonary Endarterectomy After Balloon Pulmonary Angioplasty: A Single‐Center USA Experience
Pulmonary endarterectomy (PEA) is the treatment of choice for operable chronic thromboembolic pulmonary hypertension (CTEPH), while balloon pulmonary angioplasty (BPA) is reserved for inoperable disease. However, operability is subjective and there are patients who may undergo BPA prior to PEA. It is not clear if prior BPA affects PEA outcomes. We present a series of patients from a single, high‐volume, referral center who underwent PEA after prior BPA. CTEPH patients who underwent BPA prior to undergoing PEA at the University of California, San Diego between January 2013 and July 2025 were included. Post‐PEA outcomes were compared to all PEA patients who did not have prior BPA from the year 2022. Twenty‐one patients were identified. Average number of BPA sessions prior to PEA was 3.4 ± 2.1. The most common reason for initial BPA was distal disease deemed inoperable (43%). Average total circulatory arrest time was 61.5 ± 21.8 min, compared to 47.9 ± 19.3 min ( p = 0.003) in the control PEA cases ( n = 188). Post‐operatively, the PEA after BPA cohort had longer ventilator days ( p < 0.001), ICU days ( p = 0.022) and post‐operative length of stay (LOS) ( p < 0.001); there were also higher rates of post‐operative bleeding ( p < 0.001) requiring transfusions ( p = 0.033) and return to the operating room ( p = 0.008). There was one death related to prior BPA complications despite adequate endarterectomy with improved hemodynamics. There was similar hemodynamic improvement post‐operatively in both cohorts. Although prior BPA made PEA more challenging and increased select post‐operative complications, it is not a contraindication for successful PEA.
- 29 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Open AccessPulmonary Endarterectomy After Balloon Pulmonary Angioplasty: A Single‐Center USA Experience
Pulmonary endarterectomy (PEA) is the treatment of choice for operable chronic thromboembolic pulmonary hypertension (CTEPH), while balloon pulmonary angioplasty (BPA) is reserved for inoperable disease. However, operability is subjective and there are patients who may undergo BPA prior to PEA. It is not clear if prior BPA affects PEA outcomes. We present a series of patients from a single, high‐volume, referral center who underwent PEA after prior BPA. CTEPH patients who underwent BPA prior to undergoing PEA at the University of California, San Diego between January 2013 and July 2025 were included. Post‐PEA outcomes were compared to all PEA patients who did not have prior BPA from the year 2022. Twenty‐one patients were identified. Average number of BPA sessions prior to PEA was 3.4 ± 2.1. The most common reason for initial BPA was distal disease deemed inoperable (43%). Average total circulatory arrest time was 61.5 ± 21.8 min, compared to 47.9 ± 19.3 min ( p = 0.003) in the control PEA cases ( n = 188). Post‐operatively, the PEA after BPA cohort had longer ventilator days ( p < 0.001), ICU days ( p = 0.022) and post‐operative length of stay (LOS) ( p < 0.001); there were also higher rates of post‐operative bleeding ( p < 0.001) requiring transfusions ( p = 0.033) and return to the operating room ( p = 0.008). There was one death related to prior BPA complications despite adequate endarterectomy with improved hemodynamics. There was similar hemodynamic improvement post‐operatively in both cohorts. Although prior BPA made PEA more challenging and increased select post‐operative complications, it is not a contraindication for successful PEA.
- Open Access
- 22 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Chronic Thromboembolic Pulmonary Hypertension With Cold Agglutinins Needing Pulmonary Thromboendarterectomy: The Use of Therapeutic Plasma Exchange
Cold agglutinins can be detected in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during pulmonary thromboendarterectomy (PTE) pre‐operative testing. Peri‐operative management of these patients in anticipation of deep hypothermic circulatory arrest can be challenging and has not been standardized. We describe our relevant experience and suggest a potential protocolized pre‐operative approach with this observational, retrospective cohort study. A chart review of all patients undergoing PTE surgery for CTEPH (1107 patients) at UC San Diego between 2019 and 2025 was performed. An Institutional Review Board approved quality improvement database on all patients undergoing PTE surgery was used. Twenty‐one patients (1.9%) screened positive for cold agglutinins pre‐PTE. A high co‐prevalence of antiphospholipid syndrome and cold agglutinins was noted (17/21; 81%). Thermal amplitude testing (when possible) was positive for nine patients between 15°C and 18°C. Fifteen patients underwent therapeutic plasma exchange (median of two sessions) with albumin and plasma replacement fluid followed by PTE surgery with standard cooling protocol. There were no incidents of agglutination or hemolysis peri‐ or post‐operatively. Three patients had post‐operative airway hemorrhage, two of which developed heparin‐induced thrombocytopenia (HIT). There was one mortality in the setting of HIT with recurrent thrombosis and bleeding. Median intensive care unit and hospital length of stays were 3 and 12.5 days, respectively. We suggest a protocolized approach for the identification and management of high‐risk patients with cold agglutinins, which may include therapeutic plasma exchange pre‐operatively. This can successfully mitigate the potential risk of hypothermic circulatory arrest causing agglutination during surgery.
- 22 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Open AccessChronic Thromboembolic Pulmonary Hypertension With Cold Agglutinins Needing Pulmonary Thromboendarterectomy: The Use of Therapeutic Plasma Exchange
Cold agglutinins can be detected in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during pulmonary thromboendarterectomy (PTE) pre‐operative testing. Peri‐operative management of these patients in anticipation of deep hypothermic circulatory arrest can be challenging and has not been standardized. We describe our relevant experience and suggest a potential protocolized pre‐operative approach with this observational, retrospective cohort study. A chart review of all patients undergoing PTE surgery for CTEPH (1107 patients) at UC San Diego between 2019 and 2025 was performed. An Institutional Review Board approved quality improvement database on all patients undergoing PTE surgery was used. Twenty‐one patients (1.9%) screened positive for cold agglutinins pre‐PTE. A high co‐prevalence of antiphospholipid syndrome and cold agglutinins was noted (17/21; 81%). Thermal amplitude testing (when possible) was positive for nine patients between 15°C and 18°C. Fifteen patients underwent therapeutic plasma exchange (median of two sessions) with albumin and plasma replacement fluid followed by PTE surgery with standard cooling protocol. There were no incidents of agglutination or hemolysis peri‐ or post‐operatively. Three patients had post‐operative airway hemorrhage, two of which developed heparin‐induced thrombocytopenia (HIT). There was one mortality in the setting of HIT with recurrent thrombosis and bleeding. Median intensive care unit and hospital length of stays were 3 and 12.5 days, respectively. We suggest a protocolized approach for the identification and management of high‐risk patients with cold agglutinins, which may include therapeutic plasma exchange pre‐operatively. This can successfully mitigate the potential risk of hypothermic circulatory arrest causing agglutination during surgery.
- Open Access
- 1 January 2026
- Published by XMLink in Right Heart Journal
- Vol. 1 (1)
Combination of Intravascular Lead Extraction and Epicardial Lead Placement During Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
Nemoto H, et al. Right Heart J. 2025 Oct;1(1):e2. https://doi.org/10.65721/rhj.2026.1.e2
- 1 January 2026
- Published by XMLink in Right Heart Journal
- Vol. 1 (1)
Open AccessCombination of Intravascular Lead Extraction and Epicardial Lead Placement During Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
Nemoto H, et al. Right Heart J. 2025 Oct;1(1):e2. https://doi.org/10.65721/rhj.2026.1.e2
- Open Access
- 1 January 2026
- Published by XMLink in Right Heart Journal
- Vol. 1 (1)
Differentiating Chronic Thromboembolic Pulmonary Hypertension (CTEPH) From In Situ Thrombosis of the Pulmonary Arteries: A Review of Key Distinguishing Features
Fortich M, et al. Right Heart J. 2025 Jun;1(1):e1. https://doi.org/10.65721/rhj.2026.1.e1
- 1 January 2026
- Published by XMLink in Right Heart Journal
- Vol. 1 (1)
Open AccessDifferentiating Chronic Thromboembolic Pulmonary Hypertension (CTEPH) From In Situ Thrombosis of the Pulmonary Arteries: A Review of Key Distinguishing Features
Fortich M, et al. Right Heart J. 2025 Jun;1(1):e1. https://doi.org/10.65721/rhj.2026.1.e1
- Open Access
- 18 July 2023
- Published by Elsevier in CHEST Pulmonary
- Vol. 1 (2)
Outcomes Associated With Catheter-Directed Therapies in Chronic Thromboembolic Pulmonary Hypertension
- 18 July 2023
- Published by Elsevier in CHEST Pulmonary
- Vol. 1 (2)
Open AccessOutcomes Associated With Catheter-Directed Therapies in Chronic Thromboembolic Pulmonary Hypertension
- Open Access
- 3 July 2023
- Published by Elsevier in CHEST Pulmonary
- Vol. 1 (2)
Long-term Survival and Quality of Life
- 3 July 2023
- Published by Elsevier in CHEST Pulmonary
- Vol. 1 (2)
Open AccessLong-term Survival and Quality of Life
- 2 March 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1112-1119
Distal vessel pulmonary thromboendarterectomy: Results from a single institution
- 2 March 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1112-1119
Distal vessel pulmonary thromboendarterectomy: Results from a single institution
- Open Access
- 25 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e25397
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns. Objective: The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era. Methods: Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival. Results: Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival. Conclusions: This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States. Trial Registration: ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284 International Registered Report Identifier (IRRID): DERR1-10.2196/25397
- 25 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e25397
Open AccessThe United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns. Objective: The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era. Methods: Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival. Results: Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival. Conclusions: This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States. Trial Registration: ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284 International Registered Report Identifier (IRRID): DERR1-10.2196/25397
- Open Access
- 2 November 2020
- Published by JMIR Publications Inc. in JMIR Preprints
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study (Preprint)
BACKGROUND Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns. OBJECTIVE The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era. METHODS Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival. RESULTS Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival. CONCLUSIONS This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States. CLINICALTRIAL ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25397
- 2 November 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study (Preprint)
BACKGROUND Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns. OBJECTIVE The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era. METHODS Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival. RESULTS Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival. CONCLUSIONS This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States. CLINICALTRIAL ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25397